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To enhance the therapeutic efficacy and reduce the adverse
effects of traditional Chinese medicine, practitioners often
prescribe combinations of plant species and/or minerals,
called formulae. Unfortunately, the working mechanisms of
most of these compounds are difficult to determine and
thus remain unknown. In an attempt to address the benefits
of formulae based on current biomedical approaches, we
analyzed the components of Yinchenhao Tang, a classical
formula that has been shown to be clinically effective for
treating hepatic injury syndrome. The three principal com-
ponents of Yinchenhao Tang are Artemisia annua L., Gar-
denia jasminoids Ellis, and Rheum Palmatum L., whose
major active ingredients are 6,7-dimethylesculetin (D), geni-
poside (G), and rhein (R), respectively. To determine the
mechanisms underlying the efficacy of this formula, we
conducted a systematic analysis of the therapeutic effects
of the DGR compound using immunohistochemistry, bio-
chemistry, metabolomics, and proteomics. Here, we report
that the DGR combination exerts a more robust therapeutic
effect than any one or two of the three individual com-
pounds by hitting multiple targets in a rat model of hepatic
injury. Thus, DGR synergistically causes intensified dy-
namic changes in metabolic biomarkers, regulates molec-
ular networks through target proteins, has a synergistic/
additive effect, and activates both intrinsic and extrinsic
pathways. Molecular & Cellular Proteomics 12: 10.1074/
mcp.M112.021683, 1226–1238, 2013.
Currently, a paradigm shift is occurring in that there is a new
focus on agents that modulate multiple targets simultane-
ously, rather than working at the level of single protein mole-
cules (1). Multiple-target approaches have recently been em-
ployed to design medications that are used to treat
atherosclerosis, cancer, depression, psychosis, and neurode-
generative diseases (2). During the past few years, the phar-
maceutical industry has seen a shift from the “one disease,
one target, one drug” and “one drug fits all” approaches to the
pursuit of combination therapies that include more than one
active ingredient (3, 4). Because of the complexity of medi-
cine, treatment protocols should be carefully designed, and
prescriptions must be carefully developed to successfully
fight a given disease. A growing body of evidence has dem-
onstrated that treating illnesses such as human acute promy-
elocytic leukemia (5, 6), cancer (7), HIV (8), chronic hepatitis C
(9), and diabetic nephropathy (10) with treatment regimens
that use multiple drugs for combination therapy and related
mechanisms usually amplifies the therapeutic efficacy of each
agent, yielding maximum therapeutic efficacy with minimal
adverse effects (11). Such developments represent a triumph
for modern medicine and provide fertile ground for modern
drug development (12, 13).
Interestingly, traditional Chinese medicine (TCM),1 which is
a unique medical system that assisted the ancient Chinese in
dealing with disease, has advocated combinatorial therapeu-
tic strategies for 2,500 years using prescriptions called for-
mulae (14). Typically, formulae consist of several kinds of
crude drugs that originate from medicinal plants, animals, or
minerals; one represents the principal component and is
called the monarch drug in TCM, and the others serve as
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adjuvant components that facilitate the delivery of the princi-
pal component to the disease site within the body. More
specifically, according to the rules of TCM theory, the famous
formulae include four elements: the monarch (which plays the
most important role in the formula), the minister (which in-
creases the effectiveness of the monarch herb), the assistant
(which helps the monarch and minister herbs reach their
target positions), and the servant (which can reduce the ad-
verse effects and/or increase the potency of the whole for-
mula). In formulae, the herbs work together harmoniously to
achieve an ideal therapeutic outcome. Therapeutic regimens
that include more than one active ingredient are commonly
used clinically in Chinese medicine (15). The therapeutic effi-
cacy of TCM is usually attributed to its synergistic properties,
its capacity for minimizing adverse reactions, or its improved
therapeutic efficacy. Synergism is a core principle of tradi-
tional medicine, or ethnopharmacology, and plays an essen-
tial role in improving the clinical efficacy of TCM. It is believed,
at least in regard to some formulae, that multiple components
can hit multiple targets and exert synergistic therapeutic ef-
fects (14). A scientific explanation for this type of synergy
would certainly promote the reasonable and effective appli-
cation of TCM and help to encourage rational approaches to
the safe combination of healthcare systems from various cul-
tures. Multidrug combinations are increasingly important in
modern medicine (16–18). However, the precise mechanisms
through which formulae function are poorly understood and
must be addressed using a molecular approach.
Yinchenhao Tang (YCHT), which was recorded in Shang-
hanlun, a classic resource on TCM written by Zhongjing
Zhang (150–215 A.D.), is one of the most famous Chinese
herbal formulae. YCHT consists of Artemisia annua L. (the
monarch herb), Gardenia jasminoides Ellis (the minister herb),
and Rheum Palmatum L. (the assistant and servant herb) and
has been used for more than a thousand years to treat jaun-
dice and liver disorders (19). Pharmacological studies and
clinical practice have shown that it can be used clinically to
treat cholestasis, hepatitis C, primary biliary cirrhosis, liver
fibrosis, and cholestatic liver diseases (20, 21). Our previous
study showed that YCHT contains 45 compounds, 21 of
which were detected in rat plasma (22). The compatibility of
the different compounds in YCHT and the effect on the ab-
sorption of these 19 compounds were investigated (23).
Interestingly, dimethylesculetin (D) has been shown to be
effective in treating hepatic injury (HI) by exerting hepato-
protectivity, and it contributes directly to the therapeutic ef-
fect of YCHT (24). Geniposide (G), a primary component of the
fruits of Gardenia jasminoids Ellis, exhibits various pharmaco-
logical properties, including antioxidant, anti-inflammatory,
and hepato-protective effects (25–27). Intriguingly, a recent
study showed that rhein (R), a metabolite of anthranoids and
a major component of Rheum Palmatum L., helps to amelio-
rate liver fibrosis (28–30). Studies indicate that D, G, and R
have all been used as marker compounds in quality control for
YCHT (31). It is noteworthy that a previous study reported the
synergistic effects of DGR based on the pharmacokinetics of
the main effective constituents of YCHT (32, 33). These results
demonstrate the clinical efficacy of DGR and indicate the
need for further research regarding the mechanics of this
formula.
It has been proposed that DGR-based combination treat-
ment for HI produces a synergistic effect. However, although
much is known regarding the interactions among D, G, and R
at pharmacokinetic sites, there is little knowledge regarding
the compound’s synergistic properties. Understanding the
synergistic effects of DGR represents an even greater chal-
lenge because multilayered regulation might be involved, with
the three compounds having overlapping but distinct target
properties. In order to gain insight into the complex biochem-
ical mechanisms that underlie this effective HI therapy, we
conducted an investigation incorporating advanced technol-
ogies using metabolomic, proteomic, and biochemical analy-
ses throughout the treatment process for HI (which has been
shown to respond specifically to these agents). In analyzing
the formula design in TCM, here we use the treatment of HI
with DGR as a working model. D, G, and R—which are derived
from Artemisia annua L., Gardenia jasminoids Ellis, and
Rheum Palmatum L., respectively—were used as the active
compounds in YCHT, and the efficacy and mechanisms of the
DGR combination as used to treat HI were tested both in vivo
and in vitro. This is the first study that investigates the unique
synergistic effect of combination dosing and provides support
for the popular view that traditional Chinese formulae require
multiple components to exert their combined effects.
MATERIALS AND METHODS
Reagents—Acetonitrile (HPLC grade) was purchased from Merck
(Darmstadt, Germany). Methanol (HPLC grade) was purchased from
Fisher (USA). Distilled water was purchased from Watson’s Food &
Beverage Co., Ltd. (Guangzhou, China), and formic acid (HPLC grade)
was purchased from the Beijing Reagent Company (Beijing, China).
Leucine enkephalin was purchased from Sigma-Aldrich, and carbon
tetrachloride (CCl4) was purchased from the Chemicals Factory (Tian-
jin, China). Glycerol was supplied by the Chemicals Factory. Other
chemicals, except as noted, were analytical grade. D, G, and R were
isolated within our laboratory and identified via spectral analyses,
primarily NMR and MS. After identification, the substances were
further purified via HPLC to yield authorized compound with a purity
of at least 99%. Freeze-dried YCHT powder was produced by our
laboratory. The assay kits were purchased from the Nanjing Ji-
ancheng Biotech Company (Nanjing, China). The other reagents that
were used in the two-dimensional electrophoresis were purchased
from Bio-Rad.
Animals—Male Wistar rats were bred and maintained in a specific
pathogen-free environment. The animals were allowed to acclimatize
in metabolic cages for 1 week prior to treatment. The animals were
randomly assigned to various groups and treated with D, G, and/or R
at the doses indicated in the supplementary material. The experi-
ments were performed with the approval of the Animal Ethics Com-
mittee of Heilongjiang University of Chinese Medicine, China. Blood
was collected from the hepatic portal vein, and plasma was separated
via centrifugation at 4,500 rpm for 5 min at 4 °C, flash frozen in
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liquid nitrogen, and stored at 80 °C until the liver function tests and
proteomics analyses were performed. Urine was collected daily (at
6:00 a.m.) from the metabolic cages at ambient temperature over the
course of the entire procedure and centrifuged at 10,000 rpm at 4 °C
for 5 min; the supernatants were then stored frozen at 20 °C for
subsequent metabolomic analysis.
Biochemical Analysis—We collected plasma samples in heparin-
ized tubes, kept them on ice for 1 h, and centrifuged them at 4,500
rpm for 15 min at 4 °C. We quantified the levels of plasma alanine
transaminase, aspartate transaminase, alkaline phosphatase, gluta-
thione peroxidase, and superoxide dismutase activity and the malon-
dialdehyde, triglyceride, glutamyl transferase, cholesterol, total pro-
tein, direct bilirubin, and total bilirubin content using assay kits
according to the manufacturer’s instructions. The rat livers were
removed immediately after plasma collection and stored at 70 °C
until analysis.
Histology, Immunohistochemistry, and TUNEL Assay—The livers
were fixed in 4% neutral buffered formaldehyde at 4 °C and embed-
ded in paraffin. The liver tissue was stained with H&E for histopatho-
logical analysis. Immunohistochemistry was performed using anti-
bodies against Fas and BCL-2. TUNEL staining was performed to
detect and quantify apoptotic cells using the in situ cell death detec-
tion kit. The sections were viewed and photographed using standard
fluorescent microscopic techniques.
Metabolomics Analysis—Urine and serum were collected for
UPLC-HDMS analysis. For the reversed-phase UPLC analysis, an
ACQUITY UPLC BEH C18 column (50 mm  2.1 mm inner diameter,
1.7 m, Waters Corp., Milford, MA) was used. The column tempera-
ture was maintained at 35 °C, the flow rate during the mobile phase
was 0.50 ml/min, and the injection volume was fixed at 2.0 l. Mobile
phase A involved the use of 0.1% formic acid in acetonitrile, whereas
mobile phase B involved the use of 0.1% formic acid in water. For the
urine UPLC-HDMS (Waters Corp., Milford, MA) analysis, the optimal
conditions for positive ion mode were as follows: capillary voltage of
2,500 V, desolvation temperature of 350 °C, sample cone voltage
of 35 V, extraction cone voltage of 3 V, microchannel plate voltage of
1,600 V, collision energy of 4 eV, source temperature of 110 °C, cone
gas flow of 50 l/h, and desolvation gas flow of 600 l/h. A lock mass of
leucine enkephalin at a concentration of 200 pg/ml in acetonitrile
(0.1% formic acid):H2O (0.1% formic acid) (50:50, v/v) for positive ion
mode ([MH]  556.2771) was employed via a lock-spray interface.
The data were collected in centroid mode, the lock-spray frequency
was set at 5 s, and the lock-mass data were averaged over 10 scans.
A “purge-wash-purge” cycle was employed when the auto-sampler
was used, with 90% aqueous formic acid used for the wash solvent
and 0.1% aqueous formic acid used as the purge solvent, which
ensured minimal carry-over between injections. The mass spectrom-
etry full-scan data were acquired in the positive ion mode from 100 to
1,000 Da with a 0.1-s scan time. For the plasma UPLC-HDMS anal-
ysis, the desolvation gas flow was 600 l/h, and the other parameters
were the same as for the urine. The MS data were generated and
recorded using MassLynx V4.1 (Waters Corp., Milford, MA), Marker-
Lynx Application Manager (Waters Corp., Milford, MA) was used for
peak detection, and EZinfo 2.0 software (which is included in
MarkerLynx Application Manager and can be applied directly) was
used for the principal component analysis (PCA), partial least
squares–discriminant analysis (PLS-DA), and orthogonal projection to
latent structures (OPLS) analysis. “Unsupervised” data were analyzed
using PCA, and “supervised” analysis was conducted using PLS-DA
and OPLS. Putative markers were extracted from S-plots that were
constructed following the analysis using OPLS, and markers were
chosen based on their contribution to the variation and correlation
within the data set. The processed data were then analyzed using
EZinfo 2.0 software. The potential biomarkers were matched with the
structure message of metabolites acquired from available biochemi-
cal databases, the Human Metabolome Database, and the Kyoto
Encyclopedia of Genes and Genomes.
Proteomics Analysis—Two-dimensional polyacrylamide gel elec-
trophoresis tests were performed. Protein spots with more than a
3-fold change in density (paired Student’s t test yielding p  0.05)
with consistent increases or decreases were considered as differen-
tially expressed and were selected for further identification via a
MALDI-TOF-MS/MS analysis. Details regarding the immobilized pH
gradient (IPG)-2-DE and image analysis, MALDI-TOF-MS/MS analy-
sis, and Gene Ontology (GO) functional analysis can be found in the
supplementary material. All experiments were performed at least in
triplicate to ensure reproducibility.
Statistical Analyses—All statistical analyses were performed using
Student’s t test. Differences with a p value of 0.05 or less were
considered significant. Assays were performed in triplicate, and the
results are expressed as mean  S.D.
RESULTS
Therapeutic Efficacy of DGR as Indicated by a Rat HI
Model—The efficacy of combination therapy with D, G, and R
was compared with the efficacy of monotherapy with each of
the three components individually in a rat model of HI. There
was significant variation between the biochemical indicators
for the control and model groups after CCl4 treatment (sup-
plementary Table S1). This indicates that the HI model suc-
cessfully replicated the disease. The model group had higher
alanine transaminase, aspartate transaminase, alkaline phos-
phatase, r-glutamyl transferase, triglyceride, total cholesterol
(TC), malondialdehyde, total bilirubin, direct bilirubin, and total
protein values but had lower levels of superoxide dismutase
and glutathione peroxidase than the control animals. Each
treatment group was treated back to baseline levels (i.e. those
of the control group), which demonstrates that these drugs
had a therapeutic effect in the rat HI model. Our data show
that the DGR combination statistically intensified the thera-
peutic efficacy relative to the control condition or mono-
therapy using D, G, or R (supplementary Table S1). Interest-
ingly, the DGR protocol decreased the levels of alanine
transaminase, aspartate transaminase, alkaline phosphatase,
total bilirubin, direct bilirubin, glutamyl transferase, malondi-
aldehyde, and total protein but increased the levels of gluta-
thione peroxidase, triglyceride, and total cholesterol. These
results indicate that DGR combination therapy exerted a syn-
ergistic effect and yielded better therapeutic effects than did
the approaches that were based on the use of D, G, or R as a
single agent. These data provide evidence of the synergy that
is created with co-administration. Among the various mono-
therapies, D showed the most potent therapeutic efficacy.
Our data also indicate that D is the principal component of the
formula, whereas G and R serve as adjuvant ingredients.
DGR Reduces Histologic Changes and Hepatocyte Apo-
ptosis—To confirm the protective effects of DGR in treating
liver tissue damage, histological, TUNEL, and immunohisto-
chemical analyses were performed on liver tissue that was
obtained from HI rats and compared with tissue from control
rats. Microscopic analyses of H&E- and TUNEL-stained liver
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sections showed that DGR significantly decreased hepato-
cyte necrosis, fibrotic area, and hepatocyte apoptosis levels,
making them comparable to those in normal liver (Fig. 1A).
The histopathological examination of liver sections that were
stained with H&E revealed numerous apoptotic hepatocytes
and the accumulation of massive necrosis with intralobular
hemorrhage in the livers of HI rats (Fig. 1A). Further analysis
revealed multiple and extensive areas of portal inflammation
and hepatocellular necrosis in the HI group and a moderate
increase in inflammatory cell infiltration. In the portal areas,
Kupffer cells were detected within the sinusoids. The degree
of necrosis was clearly lower in the CCL4-treated rats that
received YCHT, the DGR combination, or bitherapies using
various combinations of D, G, and R (Fig. 1A). Minimal hep-
atocellular necrosis and inflammatory cell infiltration and mild
portal inflammation were observed in rats that were treated
with either the DGR combination or YCHT as compared with
animals that were treated with the control or with monothera-
pies or biotherapies composed of D, G, and/or R. It is impor-
tant to note that only spotty necrotic hepatocytes were visible in
the livers of the DGR-treated rats. Furthermore, the H&E-stained
sections indicated that the hepatocyte size had changed in the
model rats and that DGR restored normal cell size. These results
suggest that the DGR combination prevents the destruction of
liver tissue and intensifies therapeutic efficacy.
Next, to investigate further the therapeutic and synergistic
properties of the DGR combination, apoptotic hepatocytes
were measured using TUNEL staining. Few TUNEL-positive
hepatocytes were observed in the livers of CCL4-treated rats.
However, numerous TUNEL-positive hepatocytes (p  0.01)
were found in the livers of animals that had been pretreated
with DGR, YCHT, or two agents (Fig. 1A). Interestingly, the
rats that were treated with DGR had the highest density of
apoptotic hepatocytes, and the density of apoptotic cells in
the rats that were treated with D, G, and R bitherapies was
greater than in the rats that were treated with monotherapies
(Fig. 1B). These results demonstrate that the DG, DR, and RG
combinations moderately elevated the density of apoptotic
FIG. 1. Histology, immunohistochemistry, and TUNEL assay. A, representative pictures of liver histopathology (H&E staining), immuno-
histochemistry, and TUNEL assay of apoptotic hepatocytes after CCL4 with DGR treatment in rats (original magnification:200). B, quantitative
evaluation of the density of apoptotic hepatocytes using TUNEL staining. C, quantitative immunohistochemistry evaluation of the density of
Fas- and BCL-2 positive cells. The values are expressed as mean  S.D. and were compared via analysis of variance. *p  0.05 versus the
control group; **p  0.01 versus the control group; #p  0.05 versus the HI group; ##p  0.01 versus the HI group.
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cells, and the maximum synergistic effect was observed in
rats that were treated with the DGR protocol. This is strong
evidence that the synergistic effect of D, G, and R occurred at
the level of hepatocyte apoptosis. To rigorously test this con-
clusion, we performed an extensive immunohistochemical
analysis using several various antibodies in formalin-fixed,
paraffin-embedded liver sections. This analysis was per-
formed with antibodies against Fas and BCL-2 and revealed
hepatocytes both in clusters of various sizes in the portal
areas and as single cells within the lobules (Fig. 1C). Interest-
ingly, a statistically significant difference in the density of FAS-
and BCL-2-positive cells was observed between the model
and controls. A quantitative immunohistochemical analysis
revealed that DG and DR, but not GR, induced a certain
degree of (i) up-regulation of BCL-2 (antiapoptotic) (p  0.05)
and (ii) decreased density of FAS-positive hepatocytes (p 
0.05). Surprisingly, however, the DGR combination induced a
much stronger (p  0.01) antiapoptotic effect (Fig. 1C). Al-
though G, R, and the GR combination did not dramatically
affect the staining pattern, these two compounds facilitated
the effects of D (Fig. 1C), suggesting that the use of D to
up-regulate BCL-2 is more effective when G and R are also
used. The oral administration of DGR to HI rats might be more
effective at inhibiting the extent of liver necrosis than other
treatment regimens. The immunohistochemical assay further
confirmed the cooperativity of D and G with R in up-regulating
BCL-2 and down-regulating FAS, with the strongest effect
resulting from the DGR combination, which supports the ra-
tionale of using YCHT to treat HI.
Metabolomic Multivariate Analysis—Using a Waters AC-
QUITY UPLC system together with a Waters Micromass qua-
drupole-time-of-flight Micro Synapt High Definition Mass
Spectrometer (UPLC-HDMS) under optimal conditions as de-
scribed in the supplemental material, the representative base
peak intensity chromatograms of the urine or plasma samples
that were collected from representative rats from each group
were obtained, and these are presented in Figs. 2A and 2B.
The low-molecular-mass metabolites were well separated at
11 min because of the minor particles (sub-1.7 m) of UPLC.
PCA, PLS, and OPLS-DA were used to classify the metabolic
phenotypes and identify the differentiating metabolites. Anal-
ysis of the OPLS-DA score plots identified the control and HI
rats based on differences in their metabolites, suggesting that
their metabolic profiles significantly changed as a result of
CCL4 administration (Fig. 2C). The PLS-DA loading plots dis-
played variables that were positively correlated with the score
plots (Fig. 2D). S-plots and VIP-value plots were combined for
the structural identification of the biomarkers (Fig. 2E). For
example, this information for 2-((hexyloxy)carbonyloxy)ben-
zoic acid is displayed in Fig. 2F. Finally, potential biomarkers
of significant contributions were identified, with 20 and 12 in
the urine and plasma, respectively (Fig. 3 and supplementary
Table S2). As seen in Fig. 4 and the supplementary Materials
and Methods section, putative metabolic pathways were
identified in the HI rats based on changes in the intermediates
during substance metabolism.
DGR Causes Synergistic Effects: Trajectory Analysis of HI
Rats—In this study, a model of HI rats was constructed, and
the dynamic metabolic profiles of treated rats with various
outcomes were investigated using UPLC-HDMS and multivar-
iate statistical analysis. With regard to PCA, as shown in Figs.
5A–5C, the control and model groups were significantly dif-
ferent after CCL4 treatment, which validates the HI model. Fig.
5C shows that YCHT helped prevent HI and maintained the
animals in a normal state; there were no distinct clustering
differences between the control group and the YCHT treat-
ment group. In contrast, distinct clustering differences were
observed between the model group and the groups that re-
ceived either monotherapy or bitherapy using D, G, and/or R;
each dosing regimen returned the values to their baseline
levels (i.e. those of the control group), but the DGR combina-
tion further enhanced this effect. Therefore, the maximum
synergistic effect in terms of HI prevention was observed in
rats that were treated with the DGR combination as compared
with animals that were treated with monotherapy or bitherapy
using D, G, and/or R (Figs. 5A–5C). Similarly, treatment with G
or R alone inhibited the occurrence and development of HI, as
shown by the clear differences between the control and
model groups. Among the monotherapy groups, the group
that was treated with D showed the highest level of improve-
ment. This suggests that the therapeutic effect of D on rats
with liver injury can be improved by the addition of G and R
and provides compelling evidence that the synergistic effect
of D, G, and R occurred at the metabolomic level.
DGR Triggers Dynamic Changes in Metabolic Biomark-
ers—A metabolomic trajectory analysis indicated that each
dosing regimen returned the values to their baseline levels (i.e.
those of the control group), but the maximum synergistic
effect in preventing liver injury was observed in rats that were
treated with the DGR combination, not in the animals treated
with the control or with monotherapy or bitherapy using D, G,
and/or R (Fig. 5). These results clearly show that the compo-
nents of DGR exert a mutual reinforcing effect. This raises the
question of how the DGR combination exerts its synergistic
effects. To address this question, we further utilized the
metabolomics approach to delineate metabolic changes in HI
after each treatment. Potential biomarkers were identified,
with 20 and 12 in the urine and plasma, respectively (supple-
mentary Table S2). A dynamic change analysis of the levels of
metabolic biomarkers was also used to determine whether D,
G, and/or R exerted synergistic effects. These metabolites,
when identified together, are important to the host’s response
to HI because they affect energy metabolism, amino acid
metabolism, nucleotide metabolism, and lipid metabolism.
The metabolic pathways of the biomarkers for the HI model
are presented in Fig. 4. The coefficient of variation plots (Fig.
5D) for the biomarkers indicating the metabolite concentra-
tions in the DGR group showed the high relative weights of
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FIG. 2.Metabolomic multivariate analysis. A, Base peak intensity chromatograms of urine samples. B, Base peak intensity chromatograms
of plasma samples. C, OPLS-DA score plot for the control and HI groups. (Œ, control group; f, model group). D, the PLS-DA loading plots for
the control and HI groups. E, a combination plot of S-plot and VIP values. The red point graph is the VIP value plot, which represents the value
of each metabolite. The farther from the origin, the higher the VIP value of the metabolites. F, chemical structure and mass fragment information
for 2-((hexyloxy) carbonyloxy)benzoic acid.
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these metabolite levels, thereby indicating that they had ex-
erted the greatest effect on HI. Additionally, a dynamic
change analysis of the biomarkers further validated the
metabolomic findings. Clear differences between the treat-
ment and control groups were observed with each dose.
Interestingly, the maximum synergistic effect in preventing
liver injury was observed in the rats that were treated with the
DGR protocol, whereas the animals that were treated with
monotherapy or bitherapy using D, G, and/or R showed
weaker results. Taken together, these results provide a com-
FIG. 3. Loading plots of OPLS-DA model of potential biomarkers identified. A, urine. B, plasma.
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prehensive dynamic metabolic profile and serve as the basis
for further study of the mechanisms that underlie synergism.
Metabolic pathway analysis with IPA software revealed that
metabolites that were identified together were important for
the host response to HI (Fig. 4). To uncover signal transduc-
tion pathways and/or signaling networks associated with the
differentially expressed metabolites, the identified metabolites
were imported into the IPA software. According to the IPA
knowledge base, major signaling networks, comprising 38
nodes, were associated with this set of proteins. The inte-
grated network included differentially expressed metabolites
and involved small molecular-transport-associated major sig-
naling pathways.
Proteomic Identification of the Target Proteins for HI—To
better understand CCL4-induced proteins in HI rats, we in-
vestigated dynamic proteomic differences between the model
FIG. 4. Merged network combining major signaling networks associated with the metabolites differentially expressed in the
Ingenuity pathway analysis. A, HI group; B, D group; C, DG group; D, DGR group.
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and control groups. After the two-dimensional electrophoresis
gels had been analyzed, the peptides were extracted from
each differentially expressed protein spot using in-gel trypsin
digestion, and the proteins were identified using MS/MS.
Original images of the silver-stained two-dimensional gels are
not shown in the supplementary materials. Representative
FIG. 5. DGR causes synergistic ef-
fects on trajectory analysis of HI rats.
For each cluster, dotted circles indicate
the subject closest to the average user
profile within the group. A, trajectory
analysis of PCA score plots for the HI
rats after D treatment. B, trajectory anal-
ysis of PCA score plots for the HI rats
after G treatment. C, trajectory analysis
of PCA score plots for the HI rats after R
treatment. fC, control; fM (pink), HI
group; fCOC (red), DGR group; fDG
(green); fDR (brown); fGR (yellow); fG
(blue); fD (brown); fR (green).
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two-dimensional electrophoresis images for the control and
model groups are shown in Figs. 6A and 6B. The results of the
MS/MS analysis—including the protein score, coverage,
number of identified peptides, and best ion score for each
spot—are summarized in supplementary Table S3. Among all
of the protein spots that were separated using two-dimen-
sional gel electrophoresis, 42 spots appeared to be signifi-
cantly changed in percent volume as identified by peptide
mass fingerprints that were based on MALDI-TOF-MS/MS
and database searching. We found 15 plasma proteins (7 of
which were up-regulated and 8 of which were down-regu-
lated) that were expressed in the animal model. The up-
regulated proteins in the HI group were Ig kappa chain C, zinc
finger protein 407, serotransferrin, haptoglobin, macroglobu-
lin, alpha-1-antitrypsin, and complement factor B. The down-
regulated proteins were fibrinogen alpha chain precursor,
glyceraldehyde-3-phosphate dehydrogenase, albumin, 2,4-
dienoyl-CoA reductase, transthyretin, -1-inhibitor 3, vitamin
D-binding protein, and prothrombin. The synergistically/addi-
tively regulated proteins appear to be involved in metabolism,
energy production, immunity, chaperoning, antioxidation, and
signal transduction. These data help to clarify the molecular
mechanisms that underlie the therapeutic and synergistic
properties of YCHT.
Functional Analysis of Novel Proteomic Biomarkers—To
better understand the molecular mechanisms and relevant
pathways that underlie DGR’s ability to treat HI at the pro-
teomic level, we employed a proteomics strategy that in-
volved combining two-dimensional gel electrophoresis and
MALDI-TOF-MS/MS to perform functional enrichment analy-
sis, with a special focus on the changes in the HI biological
process after each treatment. We found seven and eight
target proteins that were up-regulated and down-regulated,
respectively, and that were highly specific to the HI model
(supplementary Table S3). The detection of these proteins
with distinct regulatory patterns provides evidence that novel
biomarkers are actively involved in multifunctional pathways
that are likely essential for HI. The biological functions of these
critical proteins can be sorted into five groups: (i) generation
and degradation of the extracellular matrix, including fibrino-
gen alpha chain precursors and macroglobulin; (ii) the regu-
lation of transcription and translation, as provided by zinc
finger proteins; (iii) acute phase reaction and immunity pro-
tection, as provided by Ig kappa chain C, alpha-1-antitrypsin,
-1-inhibitor 3, prothrombin, and vitamin D-binding protein;
(iv) oxygenation and cell apoptosis, to which 2,4-dienoyl-CoA
reductase contributes; and (v) transport and metabolism, as
provided by glyceraldehyde-3-phosphate dehydrogenase,
haptoglobin, serotransferrin, and transthyretin. The character-
istic functions of these differentially expressed proteins were
enriched within clusters that were based on biological pro-
cesses such as immunity, cellular apoptosis, transport, signal
transduction, cell growth and proliferation, and metabolism.
For example, the modulation of several key members of the
immunity cluster was revealed via proteome analysis, as high-
lighted by Ig kappa chain C, -1-inhibitor 3, and prothrombin.
As expected, currently available HI biomarkers rely on the
measurement of substances that are key to the development,
transport, and metabolism of HI and thus have unlimited
clinical application value in predicting HI. These proteins
therefore may be considered as candidates for the further
FIG. 6. Two-dimensional gel electro-
phoresis representative proteomic
maps. A, the control group. B, the HI
group. C, the YCHT-treated group. D,
the DGR-treated group. The protein
spots that are indicated with numbers
represent the differentially expressed
proteins.
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investigation of synergistic mechanisms and might be poten-
tial therapeutic targets for HI.
Synergistic Effects of DGR on the Relative Expression Lev-
els of Target Proteins—Because DGR exerts preferential and
synergistic effects on the proteome, it was worthwhile to
further investigate the protein expression profiles of the model
and of each dosing group using comparative proteomics
analysis. We found that a total of 15 target proteins were
synergistically/additively modified by DGR based on two-di-
mensional gels. Figs. 6B, 6C, and 6D show the proteome
maps (two-dimensional gel electrophoresis images) for HI,
YCHT-treated, and DGR-treated rats, respectively. Supple-
mentary Table S4 summarizes the relative expression levels
(in terms of the percent volume) of these proteins. Image
analysis revealed 15 differentially expressed proteins (p 
0.01 by Student’s t test with a fold change  3.0). For the
purpose of protein identification, differentially expressed pro-
teins were isolated from the two-dimensional gel and ana-
lyzed using MS after in-gel digestion. Among these proteins,
we found a striking number of uniquely HI-associated pro-
teins. All of the details regarding the relative expression levels
for the control, model, and dosed rats are provided in sup-
plementary Table S4. For example, the amount of zinc finger
protein (spot 2) was 0.1811 in the control and down-regulated
to 0.0693 in the model group. We found that both D and G
up-regulated the zinc finger protein at the proteomic level,
whereas YCHT significantly enhanced zinc finger protein up-
regulation (0.1279). Interestingly, the DGR combination in-
duced strong expression (0.1621), reflecting potential thera-
peutic and synergistic properties of DGR in treating HI.
Equally notable is the haptoglobin protein (spot 4), which
showed strong up-regulation in the model group and down-
regulation in the YCHT, DGR, D, and G groups. In this study,
the level of alpha-1-antitrypsin (spot 6) was up-regulated in
the model rats relative to controls (indicating its importance in
liver injury), down-regulated in the YCHT and DGR groups,
and absent (not detectable) in the DG, DR, GR, D, G, and R
groups. We found that the expression of the vitamin D-binding
protein (spot 14) was slightly increased in the groups that
were treated with D (i.e. the D, DG, and DR groups) and was
dramatically up-regulated in the DGR treatment group. Al-
though G, R, and the GR combination did not exert this
significant effect, these two compounds (G and R) enhanced
the effects of D, indicating that the expression of the vitamin
D-binding protein by D can be further amplified by G and R.
This is strong evidence of a synergistic effect of D, G, and R
at the proteomic level that occurs by means of coordinated
protein expression. These observations indicate that DGR had
a synergistic/additive effect on transport, metabolism, and the
modulation of immunological processes in HI rats and that
these effects were much more pronounced with co-treatment
than with any single treatment. These data, together with the
biochemical, immunohistochemical, and metabolomic analy-
ses, suggest that D is the principal ingredient in this formula,
whereas G and R serve as adjuvant components, and that by
hitting multiple targets the DGR combination exerts more
profound therapeutic effects than either monotherapy or bi-
therapy using D, G, and/or R.
DISCUSSION
Currently, in contrast to the traditional focus on single tar-
gets, a paradigm shift is occurring that is sparking new inter-
est in agents that modulate multiple targets simultaneously
with fewer adverse effects and lower toxicity. Combination
medicines with multi-effect pathways and multi-effect targets
tend to be more effective than single drugs and might help to
address many treatment-related challenges (33). Modern
medical therapy has long acknowledged the usefulness of
combination therapies that regulate multiple nodes of the
disease network simultaneously and have a synergistic effect
on the treatment of multifactorial diseases such as acute
promyelocytic leukemia and cancer (34–36). However, con-
tinued progress will be essential if we are to develop effective,
customized multi-drug regimens. TCM, the therapeutic effi-
cacy of which is based on the combined action of a mixture of
constituents, offers new treatment opportunities. In recent
years, there has been a significant increase in the clinical use
of combinatorial intervention in TCM to achieve synergistic
interactions that are capable of producing a sufficient effect at
low doses. Most Chinese therapeutic herbs that are tradition-
ally used in co-treatment but not mono-treatment series exert
significantly better pharmacological effects. However, the
precise mechanism of synergistic action remains poorly un-
derstood. Based on syndromes and patient characteristics
and guided by the theories of TCM, formulae are designed to
contain a combination of various kinds of crude drugs that,
when combined, will achieve better clinical efficacy. One ex-
ample is YCHT, whose efficacy in treating HI has recently
been well established. Because the means of action of DGR
on HI has not been sufficiently investigated, we used an
“omics” platform and identified the key mechanisms that un-
derlie the observed effects. To gain insight into the complex
biochemical mechanisms of this effective HI therapy, we con-
ducted an investigation that incorporated modern biochemi-
cal analyses, immunohistochemistry, metabolomics, and pro-
teomics, analyzing the effects of D, G, R, DG, DR, RG, and
DGR treatments on HI. It is well known that CCl4 is a potent
hepatotoxic agent that is rapidly metabolized in vivo to the
CCl3 free radical, which subsequently acts on liver cells to
covalently conjugate membranous unsaturated lipids, leading
to lipid peroxidation; thus, CCl4 is widely used to model HI in
rats. Based on our previous metabolomics findings, we know
that YCHT can significantly prevent HI by interfering with the
trajectory changes in the biomarkers, exerting an overtly
hepatoprotective effect (20, 21). We have now tested the
therapeutic and synergistic properties of YCHT that make it
an effective treatment for HI using a rat model. We employed
UPLC-HDMS, MALDI-TOF-MS/MS, and two-dimensional gel
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electrophoresis to systematically analyze the synergism of
DGR at the levels of the proteome and metabolome, thereby
exploring some of the key molecular mechanisms that under-
lie these synergistic effects. Our approach extends the well-
established concept of combinatorial therapeutics and iden-
tifies new potential strands of investigation that involve
multicomponent combinations that target multiple pathways.
In this study, we have shown that the combined in vivo use
of the active components of YCHT (namely, D, G, and R)
exerts more profound therapeutic effects than any compo-
nent used individually in a rat model of HI. DGR significantly
intensified the therapeutic efficacy as indicated by our mod-
ern biochemical analysis. The immunohistochemical assay
further supports the cooperation of D and G with R in up-
regulating BCL-2 and down-regulating Fas, with the strongest
effect occurring with the DGR combination, thereby support-
ing the rationale of using YCHT for treating HI. These obser-
vations provide mechanistic insight into the synergistic effect.
Our metabolomic trajectory analysis indicated that each dos-
ing group could be regulated back to baseline levels (i.e.
those of the control group), but the maximum synergistic
effect on liver injury was observed in rats treated with the DGR
combination, as opposed to mono- or bitherapies. These
observations support the rationale of this formula wherein the
compounds mutually reinforce each other. We also found that
DGR activated an array of factors that are involved in energy,
amino acid, nucleotide, fatty acid, cofactor, and vitamin me-
tabolism, and we suggest that these effects might form the
basis of DGR synergy. This study has indicated that a
metabolomics approach can be used to elucidate the syner-
gistic mechanisms employed by TCM. Our study has identi-
fied robust biomarkers that are related to HI, with a special
focus on the changes in the relative expression levels of target
proteins after each treatment. It is important to note that
based on our results, DGR targets not only immunity and
metabolism but also key regulatory pathways that are used in
transport, signal transduction, and cell growth and prolifera-
tion, thereby helping to restore the normal function of the liver.
Our data will help to indicate the molecular mechanisms of
synergism at the proteomic level.
According to the rules of TCM theory, the monarch, minis-
ter, assistant, and servant herbs that constitute a formula can
work together harmoniously to achieve an ideally synergistic
and therapeutic outcome. Understanding the synergistic ef-
fects of YCHT represents an even greater challenge than
usual. This is because in YCHT, the multilayer regulation
structure involves three compounds with overlapping but dis-
tinct target properties. However, determining their targets
would shed new light on synergism and efficient therapeutic
strategies. Although the YCHT formula was designed by TCM
doctors in the pre-molecular era, its mode of function can be
revealed using modern biochemical analyses. In summary, we
have shown that TCM formulae can be analyzed using bio-
medical and chemical research approaches at the biochem-
istry, proteome, and metabolome levels. Here, we report that
the DGR-based treatment regimen yields encouraging out-
comes, reinforcing its potential use as a frontline therapy for
HI. This study can be considered as a useful pilot trial in the
effort to evaluate traditional formulae on a larger scale and to
bridge Western and Eastern medicines in this era of systems
biology. Furthermore, these observations indicate that tradi-
tional Chinese formulae usually require multiple components
to exert their effects, possibly laying the foundation for prom-
ising new schemes and patterns of drugs that are derived
from TCM.
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